JANSSEN
(JOHNSON & JOHNSON)
COVID-19 VACCINE

As of March 2021, Pfizer, Moderna, and Janssen (Johnson & Johnson) COVID-19 vaccines have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). Below are a few important facts about the Janssen (Johnson & Johnson) COVID-19 vaccine.

EFFECTIVENESS

The Janssen (Johnson & Johnson) vaccine has been proven effective at preventing serious illness, hospitalization, and death from COVID-19 disease.

SIDE EFFECTS

48.6% of participants had short-term pain at the injection site, and 33.2%–38.9% experienced side effects (e.g. fever, fatigue, headache, chills)

BOOSTER SHOT

Everyone ages 18 years and older should get a booster. Some people can also choose to receive a second booster.

People who received one dose of J&J/Janssen COVID-19 vaccine who want a booster are encouraged to get an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna).

LARGE CLINICAL TRIAL SIZE

44,000 participant randomized, double-blind, placebo-controlled trial

STORAGE & HANDLING

Stored in temperatures 36–46F

DOSING

(.5 ml) single dose

AGE RANGE

18 years and older

DC Health recommends taking the first vaccine available to you.

For more information on the COVID-19 vaccine, visit **coronavirus.dc.gov/vaccine**

DC | HEALTH
GOVERNMENT OF THE DISTRICT OF COLUMBIA

GOVERNMENT OF THE DISTRICT OF COLUMBIA
MURIEL BOWSER, MAYOR